EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, announced a strategic partnership with Integra Connect LLC designed to support life sciences companies as they develop and commercialize new oncology treatments.

Gemini Therapeutics announced Oct. 5 that the company is reducing employee headcount by 20 percent and ceasing some research and non-clinical programs as part of a corporate restructuring effort to focus on a clinical trial for geographic atrophy.

Thermo Fisher Scientific’s clinical sequencing business and AstraZeneca announced they will co-develop next-generation sequencing (NGS)-based companion diagnostics (CDx) to support AstraZeneca’s expanding portfolio of targeted therapies.

In this webinar hear from “both sides of the house” – first from an innovative information technology leader and then a senior scientist who uses the solutions provided by IT. Learn how MOMA Therapeutics’ innovative lead discovery solution can be applied to the needs of biotechnology discovery workflows.

FDA

The U.S. Food and Drug Administration on May 28 approved Amgen Inc.’s drug Lumakras for lung cancer patients with a specific mutation in a gene known as KRAS whose disease has worsened after treatment with chemotherapy or other medicines.

Alzheimer’s disease is the holy grail of pharmaceutical research, and a team of physicians published results showing that they may have found the key to actually improving cognition in patients with early-stage dementia.

Companies across the biotech and biopharma industries reported a slew of new leadership appointments, several of which have been explicitly focused on the fields of oncology and precision medicine. 

In an effort to boost drug discovery for the “toughest drug discovery problems” through the use of machine learning, precision medicines company Relay Therapeutics is acquiring Waltham, Mass.-based ZebiAI with an $85 million upfront payment.

Relay Therapeutics entered a global license and collaboration agreement with Genentech for the commercialization and development of RLY-1971, a potent inhibitor of SHP2.

BioSpace reviews whose wallets got thicker in the biopharma industry, from largest to smallest, during the Nov. 11-17 period